PERBANDINGAN COST EFFECTIVENESS ANALYSIS (CEA) PESERTA PROGRAM PENGELOLAAN PENYAKIT KRONIS (PROLANIS) DAN NON PROLANIS PADA PENYANDANG DIABETES MELITUSDI BPJS KESEHATAN TAHUN 2014 - 2016

WAKHYUNI, INDRIANTI (2017) PERBANDINGAN COST EFFECTIVENESS ANALYSIS (CEA) PESERTA PROGRAM PENGELOLAAN PENYAKIT KRONIS (PROLANIS) DAN NON PROLANIS PADA PENYANDANG DIABETES MELITUSDI BPJS KESEHATAN TAHUN 2014 - 2016. S2 thesis, Universitas Mercu Buana Jakarta-Menteng.

Preview	Text (Cover) 01 COVER PENGESAHAN PENGANTAR DAFTAR ISI.pdf Download (237kB) | Preview
Preview	Text (Abstrak) 02 ABSTRACT.pdf Download (177kB) | Preview
	Text (Bab 1) 03 BAB I.pdf Restricted to Registered users only Download (273kB)
	Text (Bab 2) 04 BAB II.pdf Restricted to Registered users only Download (134kB)
	Text (Bab 3) 05 BAB III.pdf Restricted to Registered users only Download (565kB)
	Text (Bab 4) 06 BAB IV.pdf Restricted to Registered users only Download (215kB)
	Text (Bab 5) 07 BAB V.pdf Restricted to Registered users only Download (340kB)
	Text (Bab 6) 08 BAB VI.pdf Restricted to Registered users only Download (155kB)
	Text (Daftar Pustaka & Lampiran) 09 DAFTAR PSUTAKA LAMPIRAN CV.pdf Restricted to Registered users only Download (742kB)

Abstract

An estimated of 5.1 million people in the world aged between 20 and 79 years die of diabetes mellitus in 2013 and the cost of health services for people with diabetes is 2-3 times higher than those who are not (International Diabetes Federation, 2015). In Indonesia National Health Security Program (JKN), diabetes mellitus patients are being managed in a Chronic Disease Management Program called PROLANIS. The purpose of this study is to analyze and compare the cost-effectiveness of diabetes mellitus which are managed with PROLANIS from those which are not (NON PROLANIS). The analysis and comparison run for outpatient, inpatient, emergency, and patients with complication. The calculation of cost effectiveness analysis (CEA) is done through the calculation of ACER and ICER. Research methodologies used are descriptive analysis, Kolmogorov Smirnov’s normality test, and Mann Whitney non parametric test. The result shows significant differences between costs and cases that are managed under PROLANIS and NON PROLANIS for outpatient, inpatient, and emergencies, while for patients with complications there is no significant difference of cases. PROLANIS is proven to be more cost-effective in managing diabetes mellitus than NON PROLANIS. Keywords: Diabetes Mellitus, Prolanis, ACER, ICER http://digilib.mercubuana.ac.id/ ABSTRAK Diperkirakan 5.1 juta orang di dunia yang berusia antara 20 – 79 tahun meninggal karena diabetes mellitus pada tahun 2013 dan beban biaya kesehatan bagi penyandang diabetes 2-3 kali lipat lebih berat dibandingkan bukan penyandang diabetes (International Diabetes Federation, 2015).Salah satu upaya BPJS Kesehatan untuk mengendalikan penyakit DM dan komplikasinya adalah melaksanakan program pengelolaan penyakit kronis (Prolanis). Tujuan dari studi ini adalah untuk melakukan perbandingan analisa efektivitas biaya antara Prolanis dengan Non Prolanis baik terhadap kasus dan biaya RJTL, RITL, UGD, maupun Komplikasi. Perhitungan cost effectiveness analysis (CEA) dilakukan melalui perhitungan ACER dan ICER. Metodologi penelitian yang digunakan adalah analisis deskriptif, analisis kelayakan data dan uji non parametrik Mann Whitneyy yang memberikan hasil terdapat perbedaan signifikan antara Prolanis dengan Non Prolanis baik dari kasus-biaya RJTL, RITL, UGD dan biaya komplikasi. Sedangkan untukkasus komplikasi tidak terdapat perbedaan signifikan. Prolanis merupakan program yang lebih cost effectivedibanding Non Prolanis. Kata Kunci : Diabetes Mellitus, Prolanis, ACER, ICER

Actions (login required)

View Item